Globe Life Inc. filings document operating results, governance and capital-structure disclosures for an insurance holding company focused on life and supplemental health insurance. Current reports include earnings releases furnished on Form 8-K, with disclosures on net income, net operating income, underwriting margins, premium revenue and guidance.
Proxy and governance filings cover director elections, shareholder voting results, advisory executive compensation matters, board composition, non-employee director compensation and executive retirement plan amendments. The filing record also identifies registered securities including common stock and subordinated debt, alongside recurring disclosures tied to shareholder meetings and corporate governance procedures.
Form 144 filed for Globe Life Inc. (GL) reports an intended sale of 4,500 shares of common stock through APEX CLEARING on the NYSE with an aggregate market value of $641,205 and an approximate sale date of 09/12/2025. The shares were acquired by the seller from Globe Life via stock option exercises on 02/28/2019 (2,100 shares) and 02/24/2021 (2,400 shares); the payment source for the sale is listed as proceeds of stock option exercise. The filing also discloses a sale on 09/10/2025 of 4,974 shares generating gross proceeds of $695,532.32. The filer attests not to possess undisclosed material adverse information.
Dolores L. Skarjune, Executive Vice President and Chief Administrative Officer of Globe Life Inc. (GL), reported multiple transactions dated 09/10/2025. She exercised an employee stock option to acquire 6,200 shares at an exercise price of $103.23 per share. On the same date she sold 3,354 shares at prices ranging from $139.31 to $140.01 and sold an additional 1,620 shares at prices ranging from $140.015 to $140.49. After these transactions she beneficially owned 11,037 shares directly and 2,701.527 shares indirectly through a 401(k) plan. The Form 4 was signed by an attorney-in-fact on 09/11/2025.
Globe Life Inc. Form 144 filing for proposed sale of common stock. The notice reports an intended sale of 6,200 shares of Globe Life common stock through APEX CLEARING on the NYSE with an aggregate market value of $870,852 and approximately 80,432,773 shares outstanding. The shares were acquired on 02/23/2022 via a stock option exercise from Globe Life Inc., and the proposed sale date is 09/10/2025. The filer states there were no sales by the same person in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
This Form 3 reports that Robert Sweeney, listed at the provided McKinney, TX address, filed an initial beneficial ownership statement for Globe Life Inc. (GL) related to a 07/28/2025 event. Mr. Sweeney is identified as an officer (EVP, Underwriting & Sales Adm.). The filing discloses zero shares of Globe Life common stock held directly or indirectly and references a 401(k) plan. The form is signed by an attorney-in-fact on behalf of Robert Sweeney.
Globe Life Inc. submitted a Form 13F reporting its institutional holdings. The report lists 2 holdings with a total market value of $365,007,875 as reported on the cover page. The filing was signed by Christopher T. Moore and bears an 08-08-2025 signature date.
Globe Life Inc. (GL) filed its Q2-25 Form 10-Q. Total assets rose 2.5% since YE-24 to $29.8 bn, driven by a $353 mm increase in invested assets to $19.9 bn and a $259 mm build in deferred acquisition costs. Shareholders’ equity improved to $5.42 bn from $5.31 bn as retained earnings increased $451 mm to $8.45 bn, partially offset by additional share repurchases (treasury stock up $394 mm, 16.2 mm shares held).
Policy liabilities grew 2.2% to $20.14 bn, with future policy benefits accounting for $18.85 bn. Debt remained essentially flat at $2.79 bn (short- and long-term combined), while the company’s cash position strengthened to $239 mm versus $165 mm at YE-24.
On the income side, premium revenue advanced 4.3% YoY to $1.22 bn for the quarter and 4.5% to $2.42 bn year-to-date. Net investment income ticked down 1.2% to $282 mm, and realized losses widened to $18.6 mm versus $12.6 mm a year earlier. Further earnings data were not provided in the excerpt. Common shares outstanding on 31 Jul 25 were 81.0 mm.
Globe Life Inc. (GL) – Form 4 insider activity
On 08/01/2025, EVP & Chief Strategy Officer Michael C. Majors exercised 10,000 employee stock options at an exercise price of $100.74. The newly issued shares were almost entirely sold the same day:
- Sales of 9,991 and 9 shares occurred within a $136.79–$137.78 range; weighted average disclosed at $137.41.
- Approximate gross proceeds: $1.37 million; option cost: $1.01 million.
- After the transactions, Majors holds 47,066 common shares directly, unchanged versus pre-exercise level.
- He retains 27,000 stock options (right to buy) expiring 02/26/2027.
No other equity or derivative movements were reported. The filing reflects a routine option exercise-and-sell transaction rather than an outright open-market purchase or disposal.
Globe Life Inc. (GL) – Form 4, filed 31-Jul-2025
Senior Vice-President & Chief Accounting Officer Michael Shane Henrie reported an option exercise and related sale on 29-Jul-2025:
- Option exercise (Code M): 3,250 shares at a $103.23 strike (grant dated 23-Feb-2025, expiry 23-Feb-2029).
- Open-market sale (Code S): 3,250 shares sold at a volume-weighted average price of $139.7526 (individual prices $139.67–$139.90).
Net effect on ownership
- Direct common stock declined from 6,290 to 3,040 shares (-3,250 shares).
- Indirect holdings remain 152.182 shares in the 401(k) plan.
- No remaining derivative securities from the exercised grant.
The transaction generated a spread of $36.52 per share between exercise price and sale price, indicating a gross pre-tax gain of roughly $0.12 million. Henrie continues to hold approximately 3.2 k direct shares plus 152 plan shares.